Shattuck Labs reports Phase 1 data for SL-325, sets Phase 2b start for Q3 2026
The company said Phase 1 results support advancing SL-325 into a Crohn's disease Phase 2b trial while it also unveiled a second DR3-targeting candidate, SL-846.
SEC filing